Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

H. Johnson, Daniel; M. Zobniw, Chrystia; Anh Trinh, Van; Ma, Junsheng; L. Bassett, Roland; Abdel‐Wahab, Noha; Anderson, Jaime; Davis, Jennifer; Joseph, Jocelyn; Uemura, Marc; Noman, Ali; Abu‐Sbeih, Hamzah; Yee, Cassian; N. Amaria, Rodabe; P. Patel, Sapna; A. Tawbi, Hussein; C. Glitza, Isabella; A. Davies, Michael; K. Wong, Michael; E. Woodman, Scott; Hwu, Wen-Jen; Hwu, Patrick; Wang, Yinghong; Diab, Adi

doi:10.1186/s40425-018-0412-0

Public

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Published in Journal for ImmunoTherapy of Cancer • Oct 10, 2018

Authors:

Daniel H. Johnson

Chrystia M. Zobniw

Van Anh Trinh

Abstract

BACKGROUND: Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition...

Subject

Medicine

Infliximab

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!